PIA
CBIO

Piedmont Investment Advisors’s Crescent Biopharma CBIO Stock Holding History

Piedmont Investment Advisors’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-6
Closed -$9K – 1534
2018
Q2 		$9K Buy
+6
New +$10.3K ﹤0.01% 1863

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Piedmont Investment Advisors's CBIO Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Crescent Biopharma (CBIO) in Q3 2018, closing a stake of 6 shares — an estimated $9K sold.

Piedmont Investment Advisors first reported a position in CBIO in Q2 2018 and held it in 1 quarter. The position peaked at $9K in Q2 2018. 85 funds tracked by Wall St. Rank hold CBIO as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Crescent Biopharma position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 6 Crescent Biopharma shares in Q3 2018, an estimated $9K.
  • Piedmont Investment Advisors first reported a position in Crescent Biopharma in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Crescent Biopharma position peaked at $9K in Q2 2018.
  • 85 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.